This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Clinical Trial

. 2007 Sep;8(8):509-11.

doi: 10.3816/CLC.2007.n.039.

Phase II pharmacogenomics-based adjuvant therapy trial in patients with non-small-cell lung cancer: Southwest Oncology Group Trial 0720

Gerold Bepler¹

Affiliations

PMID: 17948610
DOI: 10.3816/CLC.2007.n.039

Clinical Trial

Phase II pharmacogenomics-based adjuvant therapy trial in patients with non-small-cell lung cancer: Southwest Oncology Group Trial 0720

Gerold Bepler. Clin Lung Cancer. 2007 Sep.

. 2007 Sep;8(8):509-11.

doi: 10.3816/CLC.2007.n.039.

Author

Gerold Bepler¹

Affiliation

¹ Program and Divison of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612-9497, USA. gerold.bepler@moffitt.org

PMID: 17948610
DOI: 10.3816/CLC.2007.n.039

No abstract available

PubMed Disclaimer

Similar articles

Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.
Mazzoni F, Cecere FL, Meoni G, Giuliani C, Boni L, Camerini A, Lucchesi S, Martella F, Amoroso D, Lucherini E, Torricelli F, Di Costanzo F. Mazzoni F, et al. Lung Cancer. 2013 Nov;82(2):288-93. doi: 10.1016/j.lungcan.2013.08.018. Epub 2013 Sep 3. Lung Cancer. 2013. PMID: 24045016 Clinical Trial.
A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma.
Lv C, Ma Y, Feng Q, Fang F, Bai H, Zhao B, Yan S, Wu N, Zheng Q, Li S, Chen J, Wang J, Feng Y, Wang Y, Pei Y, Fang J, Yang Y. Lv C, et al. World J Surg Oncol. 2013 Apr 26;11:96. doi: 10.1186/1477-7819-11-96. World J Surg Oncol. 2013. PMID: 23621919 Free PMC article.
ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.
Ceppi P, Volante M, Novello S, Rapa I, Danenberg KD, Danenberg PV, Cambieri A, Selvaggi G, Saviozzi S, Calogero R, Papotti M, Scagliotti GV. Ceppi P, et al. Ann Oncol. 2006 Dec;17(12):1818-25. doi: 10.1093/annonc/mdl300. Epub 2006 Sep 15. Ann Oncol. 2006. PMID: 16980606
Pharmacogenomics and gemcitabine.
Rosell R, Cobo M, Isla D, Camps C, Massuti B. Rosell R, et al. Ann Oncol. 2006 May;17 Suppl 5:v13-16. doi: 10.1093/annonc/mdj942. Ann Oncol. 2006. PMID: 16807441 Review.
Impact of biomarkers on non-small cell lung cancer treatment.
Toschi L, Cappuzzo F. Toschi L, et al. Target Oncol. 2010 Mar;5(1):5-17. doi: 10.1007/s11523-010-0132-y. Epub 2010 May 5. Target Oncol. 2010. PMID: 20443070 Review.

See all similar articles

Cited by

ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer.
Allingham-Hawkins D, Lea A, Levine S. Allingham-Hawkins D, et al. PLoS Curr. 2010 Dec 6;2:RRN1202. doi: 10.1371/currents.RRN1202. PLoS Curr. 2010. PMID: 21152077 Free PMC article.
[Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012].
Gandara DR, Mack PC, Li T, Lara PN Jr, Herbst RS. Gandara DR, et al. Zhongguo Fei Ai Za Zhi. 2010 Mar;13(3):238-41. doi: 10.3779/j.issn.1009-3419.2010.03.16. Zhongguo Fei Ai Za Zhi. 2010. PMID: 20681067 Free PMC article. Chinese. No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information